Global Hypertrophic Cardiomyopathy Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Hypertrophic Cardiomyopathy Market was valued at $2.5 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 3.6% CAGR, to an estimated market size of $2.9 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global hypertrophic cardiomyopathy (HCM) market encompasses the diagnostic tools, pharmacological treatments, and medical devices used to manage the abnormal thickening of the heart muscle. The scope includes cardiac myosin inhibitors, beta-blockers, and calcium channel blockers, as well as implantable cardioverter-defibrillators (ICDs) and pacemakers, while excluding general cardiovascular care not specific to HCM pathology.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Hypertrophic Cardiomyopathy Market in the period 2025-30:
- The market is undergoing a major shift from symptom palliation to disease-modifying therapies, specifically driven by the adoption of selective cardiac myosin inhibitors like mavacamten.
- Increased utilization of genetic testing and cascade screening is enabling earlier identification of at-risk family members and expanding the treatable patient population.
- Advancements in multimodality imaging, including AI-enabled echocardiography and cardiac MRI, are significantly reducing the time to diagnosis for complex HCM phenotypes.
- A robust clinical pipeline focusing on precision medicine is targeting underlying sarcomere dysfunction and myocardial fibrosis to improve long-term patient outcomes.
- Rising prevalence of lifestyle-related comorbidities such as obesity and hypertension is increasing the clinical burden and demand for integrated HCM management.
- Strategic collaborations between pharmaceutical giants and biotech firms are accelerating the development of gene-based therapies for inherited cardiomyopathies.
- The expansion of specialty pharmacy networks and digital health platforms is improving patient access to high-cost, orphan-designated HCM therapeutics.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Obstructive HCM
- Non-obstructive HCM